This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and failed to respond to drugs or surgery to block the testes from making hormones and after treatment with other drugs for prostate cancer. Study of...
This clinical trial is for participants who have metastatic castration-resistant prostate cancer (mCRPC) and whose cancer progressed on or after they were previously treated with next-generation Hormonal Agent (NHA). Study of Investigational Drug, MK5684, in...
Background Information Metastatic castration-resistant prostate cancer (mCRPC) is a form of prostate cancer that keeps growing even when male hormones like testosterone are decreased to very low levels. Current treatments include drugs that block these hormones,...
Background Information: Prostate cancer, one of the most common types of cancer, becomes metastatic when it spreads to other parts of the body. Surgery or radiation alone cannot fully treat metastatic prostate cancer, so patients often undergo hormone therapy. ...
Background Information: Prostate cancer, one of the most common types of cancer, becomes metastatic when it spreads to other parts of the body. Surgery or radiation alone cannot fully treat metastatic prostate cancer, so patients often undergo hormone...
Background Information: Prostate cancer is one of the most common types of cancer. It becomes “metastatic” when it spreads to other parts of the body. Surgery or radiation alone cannot fully treat metastatic prostate cancer. Patients often need hormone therapy....
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) in Men With Hormone Sensitive Prostate Cancer and Rise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP) Darolutamide in Phase 3 Clinical Trial: For Patients with...
A research study for men with advanced prostate cancer. A Phase 3, open-label, multicenter, randomized study of Xaluritamig vs Cabazitaxel or second androgen receptor-directed therapy in subjects with Metastatic castration resistant prostate cancer previously...
